Unknown

Dataset Information

0

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice.


ABSTRACT: Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the WT1 gene are described in 10-15% of normal-karyotype AML (NK-AML) in pediatric and adult patients. Similar WT1 mutations have been reported in adult patients with myelodysplastic syndrome (MDS). WT1 mutations have been independently associated with treatment failure and poor prognosis in NK-AML. Internal tandem duplication (ITD) mutations of FMS-like tyrosine kinase 3 (FLT3) commonly co-occur with WT1-mutant AML, suggesting a cooperative role in leukemogenesis. The functional role of WT1 mutations in hematologic malignancies appears to be complex and is not yet fully elucidated. Here, we describe the hematologic phenotype of a knock-in mouse model of a Wt1 mutation (R394W), described in cases of human leukemia. We show that Wt1 +/R394W mice develop MDS which becomes 100% penetrant in a transplant model, exhibit an aberrant expansion of myeloid progenitor cells, and demonstrate enhanced self-renewal of hematopoietic progenitor cells in vitro. We crossbred Wt1 +/R394W mice with knock-in Flt3 +/ITD mice, and show that mice with both mutations (Flt3 +/ITD/Wt1 +/R394W) develop a transplantable MDS/MPN, with more aggressive features compared to either single mutant mouse model.

SUBMITTER: Annesley CE 

PROVIDER: S-EPMC6219680 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in mice.

Annesley Colleen E CE   Rabik Cara C   Duffield Amy S AS   Rau Rachel E RE   Magoon Daniel D   Li Li L   Huff Vicki V   Small Donald D   Loeb David M DM   Brown Patrick P  

Oncotarget 20181019 82


Wilms tumor 1 (WT1) is a zinc finger transcriptional regulator, and has been implicated as both a tumor suppressor and oncogene in various malignancies. Mutations in the DNA-binding domain of the <i>WT1</i> gene are described in 10-15% of normal-karyotype AML (NK-AML) in pediatric and adult patients. Similar <i>WT1</i> mutations have been reported in adult patients with myelodysplastic syndrome (MDS). <i>WT1</i> mutations have been independently associated with treatment failure and poor prognos  ...[more]

Similar Datasets

| S-EPMC3876267 | biostudies-literature
| S-EPMC5342464 | biostudies-literature
| S-EPMC5339673 | biostudies-literature
| S-EPMC3327463 | biostudies-literature
| S-EPMC3932758 | biostudies-literature
| S-EPMC9536269 | biostudies-literature
| S-EPMC9258203 | biostudies-literature
| S-EPMC4034537 | biostudies-literature
| S-EPMC3722971 | biostudies-other
| S-EPMC5045383 | biostudies-literature